

# FUNDING AND REIMBURSEMENT MODELS FOR PHARMACY-BASED VACCINATION

This infographic outlines how seven countries finance and reimburse vaccination services in pharmacies. It also highlights the economic and healthcare benefits of pharmacist-led vaccination programmes, including cost-savings, improved coverage, and reduced strain on healthcare systems.



## PHARMACY-BASED VACCINATION REIMBURSEMENT MODELS



### CANADA

Operates under a **single reimbursement model** for healthcare services, where public (province-run) health systems or insurers handle the reimbursement process.<sup>1</sup>



### FRANCE

**Reimbursement** is standardised across the public health system or insurers.<sup>1</sup> Vaccine administration without prescribing by the pharmacist is reimbursed at EUR 7.50, including VAT. Vaccinations that involve prescribing and administration by the pharmacist are reimbursed at EUR 9.60, including VAT.<sup>2</sup>



### USA

**Three reimbursement models** for healthcare services:<sup>1</sup>

- Reimbursement by public (state-run) health systems or insurers.
- Reimbursement by private health systems or insurers.
- Paid for by the patient.



### AUSTRALIA

**Two reimbursement models** for healthcare services:<sup>1</sup>

- Reimbursement by public (state-run) health systems or insurers.
- Paid for by the patient.

**Under the National Immunisation Programme (NIP)**, vaccines are provided free of charge, but pharmacies can charge for administering them unless reimbursed by the government.<sup>2</sup>

**Pharmacies administering COVID-19 vaccines** receive administration fees of AUD 27.35 (EUR 11.86) (urban) and AUD 30.50 (EUR 18.80) (rural), with extra compensation for off-site visits.<sup>3</sup>

**Additional remuneration** is provided for specific state-funded vaccination programmes, such as flu and Japanese encephalitis vaccines.<sup>2</sup>

**Since July 2024**, the Australian Government pays AUD 19.32 (EUR 11.84) per NIP vaccine administered.<sup>3</sup>



### IRELAND

**Two reimbursement models** for vaccination services:<sup>1</sup>

- Reimbursement by public (state-run) health systems or insurers.
- Paid for by the patient.

**COVID-19 and seasonal flu vaccines** are fully reimbursed by the State for community pharmacies.<sup>4</sup> Free vaccines for at-risk groups.<sup>5</sup>

**Additional incentives are provided** to increase COVID-19 vaccination rates.<sup>2</sup>

**Both pharmacists and GPs receive equal compensation for administering vaccines**, promoting fairness across healthcare professionals.<sup>4</sup>



### PORTUGAL

**Three reimbursement models** for healthcare services:<sup>1</sup>

- Reimbursement by public (state-run) health systems for eligible patients
- Reimbursement by private
- Paid for by the patients.

**Initially**, patients paid for pharmacy-based vaccination services out-of-pocket. Over time, insurance companies and corporations began covering the costs.<sup>4</sup>

**Since the 2023-24**, the National Health System (NHS) reimburses vaccination services for designated age groups, ensuring broader access to essential vaccines.<sup>4</sup>

**National vaccination campaign<sup>5</sup>**

- In 2023, the Ministry of Health included community pharmacies in the in the seasonal vaccination campaign.
- Coadministration of Influenza and COVID-19 vaccines is offered.
- Pharmacies are now reimbursed for vaccination services under the national health budget.



### UK


**Three reimbursement models** for healthcare services:<sup>1</sup>

- Reimbursement by public (state-run) health systems or insurers.
- Reimbursement by private health systems or insurers.
- Paid for by the patient.








**In England**, pharmacies receive separate reimbursements for vaccine costs and service fees under NHS-funded vaccination programs.<sup>4</sup> For the 2024/25 season, pharmacies are paid GBP 9.58 (EUR 11.46) per flu vaccine administered, along with reimbursement for the cost of the vaccine based on its current basic price.<sup>4,6</sup> Additionally, an extra fee of GBP 2.50 (EUR 2.99) is provided for COVID-19 vaccines administered outside the flu season.<sup>4</sup>



## REIMBURSEMENT MODELS ACROSS 7 COUNTRIES<sup>1</sup>

							
Reimbursement by public (state-run) health systems or insurers	✓	✓	✓	✓	✓	✓	✓
Reimbursement by private health systems or insurers					✓	✓	✓
Paid for by the patient	✓			✓	✓	✓	✓

## PHARMACY PAYMENTS COMPARISON<sup>2,3,7,8</sup>

COUNTRIES	REIMBURSEMENT
<b>AUSTRALIA</b> 	AUD 27.35 (EUR 16.86) for COVID-19 vaccines (urban) AUD 30.50 (EUR 18.80) for COVID-19 vaccines (rural) AUD 19.32 (EUR 11.84) for NIP vaccines from July 2024
<b>CANADA</b> 	Varies depending on the third-party payer or province
<b>FRANCE</b> 	EUR 7.50 (incl. VAT): Vaccine administration only EUR 9.60 (incl. VAT): Vaccine administration + prescribing
<b>IRELAND</b> 	EUR 15 for the Influenza vaccine
<b>PORTUGAL</b> 	EUR 3 per vaccine administrated, with an additional EUR 0.11 if waste is generated by the pharmacy
<b>UK</b> 	In England, GBP 9.58 (EUR 11.46) per NHS-funded vaccine Additional GBP 2.50 (EUR 2.99) for COVID-19 vaccines outside the flu season
<b>USA</b> 	Varies depending on the third-party payer or state

## PHARMACY-DRIVEN VACCINATIONS: BOOSTING HEALTHCARE OUTCOMES AND EFFICIENCY



According to a recent report by the Office of Health Economics, adult vaccination against four diseases (seasonal influenza, pneumococcal disease, herpes zoster, and respiratory syncytial virus (RSV)), can return up to 19 times their initial investment to society, when their benefits beyond the healthcare system are monetised.<sup>9</sup>



Pharmacies can increase vaccination coverage during influenza epidemics, potentially mitigating up to 23.7 million symptomatic cases, saving third-party payers up to USD 2.8bn (EUR 2.65bn), and providing society with USD 99.8bn (EUR 94.32bn) in savings.<sup>10</sup>



Global Health benefits of potentially effective vaccines for NCDs: 74% of deaths globally and over 64% of all disability-adjusted life-years (DALYs).<sup>11</sup>



Pharmacist-led interventions, such as proactive communication and in-pharmacy dialogues, substantially increase vaccination rates compared to standard care.<sup>12</sup>



Shifting vaccination services to pharmacies reduces the burden on traditional healthcare providers, allowing physicians to dedicate more time to critical patient care activities.<sup>13</sup>



Preventing infections through vaccinations helps mitigate the exacerbation of non-communicable diseases (NCDs), reducing the healthcare burden and the social and economic impact of diseases.<sup>4</sup>



Vaccinations reduce hospital emergency visits, ease pressure on healthcare systems, and lower hospitalisation costs.<sup>4</sup>

### References

1. International Pharmaceutical Federation (FIP) Leveraging pharmacy to deliver life-course vaccination: An FIP Global intelligence report. The Hague: International Pharmaceutical Federation [Internet]. 2024. [Cited: 20 September 2024]. Available at: <https://www.fip.org/file/5851>.
2. International Pharmaceutical Federation (FIP). Pharmacy-based vaccination: Recent developments, success stories and implementation challenges. The Hague: (FIP) [Internet]. 2023. [Cited: 19 September 2024]. Available at: <https://www.fip.org/file/5704>.
3. Pharmacy Programs Administrator. National Immunisation Program Vaccination in Pharmacy (NIPVIP) Program. Available at: <https://www.ppaonline.com.au/programs/national-immunisation-program-vaccinations-in-pharmacy-program>.
4. International Pharmaceutical Federation (FIP). Global vaccination policy development summit. The Hague: International Pharmaceutical Federation; 2024. Available at: <https://www.fip.org/file/6039>.
5. Pharmaceutical Group of the European Union (PGEU). PEGU Position Paper on the Role of Community Pharmacists in Vaccination. Brussels: (PGEU) [Internet]. 2023. Available at: <https://www.pgeu.eu/wp-content/uploads/2023/11/The-role-of-community-pharmacists-in-vaccination-PGEU-Position-Paper.pdf>.
6. National Health Services (NHS). What will I be reimbursed for providing the flu vaccination service? [Internet]. [cited 2024 Nov 26]. Available at: <https://faq.nhsbsa.nhs.uk/knowledgebase/article/KA-03156/en-us>.
7. European Houle SK, Grindrod KA, Chatterley T, Tsuyuki RT. Publicly funded remuneration for the administration of injections by pharmacists: An international review. *Can Pharm J (Ott)*. 2013;146(6):353-64. Available at: <https://pubmed.ncbi.nlm.nih.gov/24228051/>.
8. República Dd. Portaria n.º 206/2024/1, de 12 de setembro: Diário da República; 2024. Available at: <https://diariodarepublica.pt/dr/detalhe/portaria/206-2024-887449715>.
9. The Socioeconomic Value of Adult Immunisation Programmes. OHE Contract Research Report: Office of Health Economics. Available at: <https://www.ohe.org/publications/the-socio-economic-value-ofadult-immunisation-programmes/>.
10. Bartsch SM, Taitel MS, DePasse JV, Cox SN, Smith-Ray RL, Wedlock P, et al. Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic. *Vaccine*. 2018;36(46):7054-63. Available at: <https://pubmed.ncbi.nlm.nih.gov/30340884/>.
11. Institute for Health Metrics and Evaluation. GBD Results 2021. Available at: <https://vizhub.healthdata.org/gbd-results/>.
12. Murray E, Bieniek K, Del Aguila M, Egodage S, Litzinger S, Mazouz A, et al. Impact of pharmacy intervention on influenza vaccination acceptance: a systematic literature review and meta-analysis. *Int J Clin Pharm*. 2021;43(5):1163-72. Available at: <https://pubmed.ncbi.nlm.nih.gov/34047881/>.
13. Kirkdale CL, Nebout G, Megerlin F, Thornley T. Benefits of pharmacist-led flu vaccination services in community pharmacy. *Ann Pharm Fr*. 2017;75(1):3-8. Available at: <https://pubmed.ncbi.nlm.nih.gov/27717412/>.